Page 5 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Luke walkerNoura choudhuryExchange commissionHarpoon therapeutics incEuropean society of medical oncology congressPresent interim tolerabilityResponse dataEuropean societyMedical oncology congressActivating constructChief medical officerInterim resultsT cell engagerSmall cell lung cancerNeuroendocrine neoplasmsHarpoon therapeutics

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Luke walkerNoura choudhuryEuropean society of medical oncology congressHarpoon therapeutics incExchange commissionHarpoon therapeuticsEuropean societyMedical oncology congressActivating constructChief medical officerInterim resultsT cell engagerSmall cell lung cancerNeuroendocrine neoplasmsPrivate securities litigation reform actHarpoon therapeutic

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome , No ICANS – Phase 1 data set, including recommended Phase 2.

Luke walkerGlobenewswire incInternational myeloma societyExchange commissionHarpoon therapeutics incActivating constructMyeloma societyAnnual meetingChief medical officerPrivate securities litigation reform actHarpoon therapeuticHarpoon therapeutics

HARPOON THERAPEUTICS ANNOUNCES FIRST PATIENTS WITH SMALL CELL LUNG CANCER DOSED IN HPN328 COMBINATION COHORT

SOUTH SAN FRANCISCO - Harpoon Therapeutics, Inc. , a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer .

New yorkUnited statesLuke walkerRoberth uhlHarpoon therapeutics incEuropean society for medical oncologyExchange commissionMaster clinical supply agreementHoffmann la rocheChief medical officerAtezolizumab combinationMedical oncologyActivating constructPrivate securities litigation reform actRisk factorNews publishing

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesLuke walkerRoberth uhlHarpoon therapeutics incRoche ltdExchange commissionEuropean society for medical oncologyMaster clinical supply agreementChief medical officerAtezolizumab combination cohortEuropean societyMedical oncologyInvestor relationsActivating constructHarpoon therapeutics